Gut bacterial profiles in Parkinson's disease: A systematic review.
Zhe LiHongfeng LiangYingyu HuLin LuChunye ZhengYuzhen FanBin WuTao ZouXiaodong LuoXinchun ZhangYan ZengZiyan LiuZhicheng ZhouZhenyu YueYi RenZhuo LiQiaozhen SuPing-Yi XuPublished in: CNS neuroscience & therapeutics (2022)
Our review shows that the involvement of the gut microbiome in the etiology of PD may involve alterations of short-chain fatty acids (SCFAs)-producing bacteria and an increase in putative gut pathobionts. SCFAs-producing bacteria may vary above or below an "optimal range," causing imbalances. Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, increased Bifidobacterium and Lactobacillus in the PD gut microbiome may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging.